administr
hyper
immun
sera
prevent
treat
lifethreaten
infect
remark
mileston
medicin
biotechnolog
achiev
centuri
ago
yet
therapeut
use
monoclon
antibodi
field
develop
slowli
last
decad
compar
contrast
current
method
gener
human
monoclon
antibodi
highlight
advantag
exploit
human
antibodi
repertoir
use
novel
method
allow
effici
immort
clone
human
memori
b
cell
method
success
appli
isol
broadli
neutral
antibodi
sar
influenza
virus
expect
acceler
develop
therapeut
field
infecti
diseas
provid
neutral
antibodi
passiv
serotherapi
also
gener
relev
inform
vaccin
design
polyclon
immunoglobulin
ig
isol
hyper
immun
sera
anim
human
origin
confer
immedi
protect
pathogen
toxin
practic
introduc
von
behr
kitasato
extens
use
prophylact
therapeut
set
howev
polyclon
sera
sever
problem
use
heterolog
protein
difficulti
find
immun
donor
risk
relat
use
human
blood
product
monoclon
antibodi
repres
ideal
altern
polyclon
sera
method
produc
antibodi
avail
recent
year
develop
infecti
diseas
field
develop
slowli
inde
current
one
monoclon
antibodi
market
prevent
respiratori
syncyti
viru
rsv
infect
newborn
recent
year
develop
monoclon
antibodi
technolog
serotherapi
found
novel
applic
field
chronic
inflammatori
autoimmun
diseas
cancer
strike
exampl
provid
antibodi
neutral
inflammatori
cytokin
tumor
necrosi
factor
tnf
autoimmun
diseas
antibodi
enhanc
cell
respons
cancer
cell
target
inhibitori
receptor
cytotox
tlymphocyt
deplet
transform
autoreact
b
cell
target
molecul
current
human
fulli
human
monoclon
antibodi
market
mani
differ
stage
develop
spite
slow
progress
sever
reason
believ
human
monoclon
antibodi
find
relev
indic
field
infecti
diseas
inde
urgent
need
therapi
infecti
agent
vaccin
convent
therapi
lack
indic
rang
emerg
pathogen
influenza
viru
sar
coronaviru
west
nile
dengu
virus
bioterror
agent
smallpox
anthrax
establish
human
pathogen
cytomegaloviru
cmv
hepat
c
viru
hcv
hepat
b
viru
hbv
bacteria
caus
nosocomi
infect
immun
suppress
patient
sever
exampl
past
recent
studi
document
effect
serotherapi
infecti
agent
anim
model
human
evid
sera
collect
convalesc
donor
confer
protect
pandem
influenza
emerg
viru
polyclon
immunoglobulin
cmvimmun
donor
protect
fetu
given
mother
infect
cmv
hbv
hyperimmun
globulin
prevent
reinfect
transplant
liver
monoclon
antibodi
shown
prevent
infect
mucos
tissu
monkey
model
hiv
infect
final
low
dose
singl
monoclon
antibodi
west
nile
viru
shown
suffici
protect
mice
infect
higher
dose
antibodi
cure
mice
alreadi
infect
harbor
viru
brain
human
monoclon
antibodi
infecti
agent
repres
attract
option
sinc
high
specif
long
halflif
lack
side
effect
synerg
antivir
antimicrobi
therapi
furthermor
polyclon
sera
given
high
amount
repeat
intraven
infus
monoclon
antibodi
could
administ
intramuscular
inject
much
smaller
volum
clinic
experi
indic
singl
antibodi
rsv
suffici
prevent
infect
newborn
reason
believ
cocktail
least
two
monoclon
antibodi
recogn
nonoverlap
epitop
may
effect
prevent
select
escap
mutant
may
necessari
highli
variabl
virus
establish
chronic
infect
hcv
given
consider
clear
bottleneck
develop
monoclon
antibodi
therapeut
infecti
diseas
rest
avail
high
throughput
method
select
potent
broadli
neutral
antibodi
sourc
antibodi
method
use
isol
consid
principl
human
monoclon
antibodi
isol
three
sourc
immun
individu
immun
mice
synthet
antibodi
librari
advantag
disadvantag
approach
may
guid
choic
appropri
method
given
target
tabl
isol
antibodi
immun
donor
offer
advantag
fulli
exploit
strength
human
antibodi
respons
human
pathogen
inde
human
antibodi
peculiar
featur
long
select
larg
number
precursor
target
multipl
epitop
high
affin
importantli
human
immun
system
expos
relev
antigen
display
infect
agent
consequ
mount
broad
respons
epitop
point
best
illustr
fact
broadli
neutral
monoclon
antibodi
avail
today
isol
b
cell
infect
individu
context
worth
emphas
vaccin
pathogen
broad
spectrum
respons
human
popul
consequ
possibl
identifi
donor
make
particularli
effect
antibodi
respons
shown
recent
case
human
sourc
appear
ideal
isol
antibodi
human
pathogen
principl
suitabl
isol
antibodi
human
antigen
cytokin
cell
surfac
molecul
human
immun
system
toler
although
may
except
rule
mice
carri
human
immunoglobulin
loci
humic
produc
human
antibodi
respons
immun
mice
readili
produc
antibodi
human
antigen
follow
appropri
immun
human
monoclon
antibodi
isol
use
classic
hybridoma
technolog
altern
method
mous
system
therefor
particularli
suitabl
isol
antibodi
specif
human
antigen
cytokin
cell
surfac
molecul
less
suitabl
human
pathogen
hiv
hcv
hbv
cmv
infect
mice
addit
immun
respons
mice
often
suboptim
possibl
mismatch
human
ig
mous
fc
receptor
random
synthet
librari
human
immunoglobulin
ig
gene
display
phage
yeast
becom
standard
method
isol
human
monoclon
antibodi
sinc
adapt
antigen
lead
antibodi
high
affin
repeat
cycl
affin
matur
signific
drawback
howev
target
antigen
must
known
priori
sinc
select
base
bind
purifi
antigen
function
assay
ie
viral
neutral
view
consider
target
human
b
cell
respons
repres
direct
effect
approach
isol
neutral
antibodi
infecti
agent
effect
scale
mammalian
express
system
discuss
opportun
offer
human
immun
respons
consid
advantag
target
human
plasma
cell
versu
memori
b
cell
isol
human
monoclon
antibodi
newli
gener
plasma
cell
secret
specif
antibodi
high
rate
recov
high
number
puriti
peripher
blood
within
narrow
time
window
peak
immun
respons
day
booster
immun
cell
migrat
bone
marrow
persist
longliv
plasma
cell
account
small
proport
total
plasma
cell
pool
therefor
consequ
biolog
plasma
cell
access
blood
narrow
time
window
precis
defin
case
booster
immun
difficult
predict
case
natur
infect
addit
approach
offer
possibl
select
high
respond
donor
small
number
plasma
cell
isol
blood
bone
marrow
lack
appropri
fusion
partner
sever
limit
use
hybridoma
technolog
isol
monoclon
antibodi
plasma
cell
therefor
reli
clone
express
ig
gene
done
use
phage
display
librari
scrambl
vh
vl
gene
isol
bone
marrow
plasma
cell
recent
isol
pair
vh
vl
gene
plasma
cell
use
singl
cell
pcr
use
latter
method
possibl
isol
sever
human
monoclon
antibodi
tetanu
toxoid
influenza
viru
boost
individu
memori
b
cell
known
persist
lifetim
therefor
repres
ideal
repositori
antibodi
specif
gener
individu
follow
infect
vaccin
access
time
prime
take
small
sampl
peripher
blood
contrast
plasma
cell
termin
differenti
memori
b
cell
retain
substanti
growth
potenti
immort
epstein
barr
viru
ebv
ebvimmort
b
cell
secret
antibodi
larg
amount
screen
detect
specif
antibodi
perform
cultur
supernat
use
bind
assay
also
function
assay
addit
ebvimmort
b
cell
also
retain
express
surfac
ig
consequ
select
antigen
bind
capac
sever
method
avail
purifi
plasma
cell
memori
b
cell
produc
specif
antibodi
use
fluorochrometag
antigen
antigenspecif
memori
b
cell
includ
ebvb
cell
display
specif
antibodi
cell
surfac
directli
stain
antigen
plasma
cell
lack
surfac
ig
stain
secret
antibodi
captur
cell
surfac
via
piggyback
antiig
antibodi
method
depend
known
purifi
antigen
lead
isol
bind
antibodi
use
ebv
immort
human
memori
b
cell
report
year
ago
impact
field
modest
low
effici
b
cell
immort
difficulti
clone
immort
b
cell
matter
fact
method
abound
last
year
favour
altern
method
human
mous
antibodi
select
phagedisplay
librari
immun
mice
carri
human
ig
loci
recent
found
addit
tlr
agonist
instanc
agonist
cpg
increas
effici
ebv
bcell
immort
facilit
clone
immort
b
cell
method
fulli
exploit
potenti
human
immun
respons
particular
possibl
select
donor
mount
particularli
effect
antibodi
respons
target
pathogen
analyz
serum
antibodi
immort
memori
b
cell
rapid
isol
b
cell
clone
produc
monoclon
antibodi
antibodi
secret
cultur
supernat
screen
use
bind
importantli
neutral
assay
context
worth
emphas
antibodi
bind
viral
glycoprotein
also
neutral
activ
sinc
epitop
display
infecti
viral
particl
b
cell
clone
isol
use
ebv
method
stabl
secret
antibodi
high
rate
mgl
cultur
supernat
facilit
antibodi
product
preclin
studi
figur
proof
principl
abl
rapidli
isol
monoclon
antibodi
neutral
sar
coronaviru
memori
b
cell
infect
donor
interestingli
antibodi
potent
neutral
activ
vitro
vivo
recent
four
antibodi
shown
neutral
sar
coronavirus
avail
includ
three
human
two
anim
isol
b
rock
corti
et
al
submit
two
antibodi
epitop
recogn
map
receptorbind
site
third
antibodi
recogn
distinct
site
base
find
would
possibl
formul
cocktail
two
three
antibodi
broadli
neutral
recogn
nonoverlap
epitop
order
provid
broad
protect
minim
risk
select
escap
mutant
similar
process
isol
small
sampl
frozen
pbmc
two
patient
recov
infect
sever
human
monoclon
antibodi
neutral
vitro
vivo
notabl
antibodi
work
also
therapeut
set
sinc
protect
mice
even
given
three
day
inject
lethal
infecti
dose
addit
sever
antibodi
found
neutral
clade
clade
virus
besid
applic
respons
emerg
pathogen
method
find
also
suitabl
character
antibodi
respons
complex
pathogen
plasmodium
falciparum
case
human
monoclon
antibodi
isol
character
respons
molecul
mediat
adhes
infect
erythrocyt
placent
endothelium
project
ongo
author
laboratori
hcv
cmv
dengu
viru
demonstr
gener
applic
method
applic
b
cell
immort
method
may
go
far
beyond
infecti
diseas
inde
sever
studi
shown
autoantibodi
cytokin
produc
patient
inflammatori
diseas
even
normal
individu
small
fraction
cancer
patient
mount
antibodi
respons
antigen
express
tumor
cell
possibl
autoreact
antibodi
isol
donor
may
find
applic
diagnost
therapeut
pharmaceut
biotechnolog
schemat
view
analyt
vaccinolog
approach
ongo
project
author
laboratori
modifi
burton
et
al
improv
method
immort
human
memori
b
cell
two
aspect
pathogen
repres
consider
challeng
vaccin
design
complex
eg
herp
virus
bacteria
parasit
genet
variabl
eg
hcv
influenza
viru
ration
vaccin
design
rest
identif
molecul
promot
pathogen
invas
patholog
case
variabl
pathogen
conserv
epitop
within
molecul
sequenc
pathogen
genom
consider
facilit
design
vaccin
complex
pathogen
process
defin
revers
vaccinolog
though
approach
remain
labour
intens
major
challeng
howev
identifi
conserv
epitop
within
highli
variabl
viral
glycoprotein
analysi
human
immun
respons
isol
neutral
antibodi
offer
shortcut
solut
challeng
pathogen
complex
variabl
process
analyt
vaccinolog
start
isol
neutral
antibodi
use
probe
identifi
target
molecul
conserv
epitop
appropri
formul
vaccin
figur
approach
origin
propos
burton
et
al
solv
hiv
vaccin
problem
implement
intern
consortium
work
identifi
conserv
structur
spike
glycoprotein
work
led
identif
epitop
recogn
four
broadli
neutral
antibodi
substanti
limit
small
number
antibodi
avail
expect
memori
b
cell
immort
method
greatli
facilit
discoveri
process
complex
variabl
pathogen
reciproc
fashion
identif
target
diseas
enhanc
antibodi
may
provid
ration
approach
design
safer
vaccin
minim
risk
immunopatholog
